

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/45753 A2

(51) International Patent Classification⁷: **A61K 47/00**

(21) International Application Number: PCT/EP01/14189

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00204388.3 8 December 2000 (08.12.2000) EP

(71) Applicant: **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76,
NL-6824 BM Arnhem (NL).

(72) Inventors: **EGBERINK, Johannes, Gerardus, Joseph**;
N.V. Organon, Postbus 20, NL-5340 BH Oss (NL). **ENGELHART, John, Francis**; Organon Inc., 375 Mt. Pleasant Ave, West Orange, NJ 07092 (US).

(74) Agent: **KRAAK, Hajo**; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL FORMULATION OF GEPIRONE FOR ORAL ADMINISTRATION

(57) Abstract: This invention makes a pharmaceutical formulation for oral administration with extended release properties available comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount of the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt%, the amount of carbohydrate binder is from 7 to 10 wt% and the amount of gepirone hydrochloride is from 13 to 21 wt%. The formulation is useful for a treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for extended release of gepirone.

WO 02/45753 A2

PHARMACEUTICAL FORMULATION OF GEPIRONE FOR ORAL ADMINISTRATION

The invention relates to a pharmaceutical formulation for oral
5 administration with extended release properties comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose.

Such pharmaceutical formulations are described in EP 700 680 for use in
10 the treatment of CNS disorders such as anxiety, depression and panic disorders. Gepirone is a drug which induces undesirable effects when high peak levels are reached. An even distribution of drug levels in blood is desirable to have a suitably tolerated therapeutic dose level. It was reported that optimal treatment of major depressive disorder was obtained
15 with daily doses of up to 100 mg gepirone HCl (Wilcox et al; Psychopharmacology Bulletin). The administration of the total daily amount of gepirone was spread over the day by providing 20 mg gepirone HCl extended release tablets at intervals during the day. This was done not only because it was indicated in the prior art (EP 700 680) that
20 extended release formulations can reliably be produced and have slow release properties when the content is at most 12% gepirone HCl of the total content, with a preferred maximum of 11 wt %, and the content of microcrystalline cellulose at least 10% with a preferred minimum of 11 wt %, but also because it could be expected that once-a-day high doses will
25 be badly tolerated even when given as an extended release formulation.

Contrary to what is to be expected it was found that suitable higher strengths extended release tablets can be prepared and are well tolerated in a once a day dosage form in those patients already habituated to lower
30 dosages.

Clearly, it is more accommodating for such patients to have a once-a-day formulation available.

35 This invention makes a pharmaceutical formulation according to the opening paragraph available in which the amount of the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt %, the amount of carbohydrate binder is from 7 to 10 wt % and the amount of gepirone

CONFIRMATION COPY

hydrochloride is from 13 to 21 wt %. The formulation may optionally contain further pharmaceutically acceptable additives, such as glidants, lubricants and colorants.

- 5 The invention makes a once per day medical treatment available with gepirone HCl in a pharmaceutical formulation for oral administration having the above-defined composition. This treatment is useful and well-tolerated by those patients treated for depression or a related central nervous system disorder, who are started on a treatment regime beginning
10 with doses of about 20 mg gepirone HCl per day, and which is gradually built up to 60-100 mg gepirone HCl per day.

A pharmaceutical formulation for oral administration is usually a tablet or a capsule. Contrary to what would have been the weight of an 80 mg
15 tablet according to EP 700 680, tablets according to the present invention can have a total weight of at most 450 mg. Despite the high relative amount of gepirone HCl over the cellulosic polymer matrix material and also over the carbohydrate binder, oral formulations, in particular tablets, could still be made with acceptable dissolution properties of gepirone and
20 sufficient stability during production and handling.

A pharmaceutically acceptable cellulosic polymer matrix has the function of retaining gepirone HCl so that an extended release effect is obtained. Suitable matrixes include hydroxyalkylsubstituted alkylcelluloses having a
25 viscosity of 15,000 cps to 100,000 cps. Hydroxymethyl propylcellulose (HPMC) of grades K15M and K100M is preferred and grade K100M, Premium (Methocel) is in particular preferred. The amounts of components in the pharmaceutical formulation of the invention are expressed as weight percentage (wt %) of the total weight of the
30 formulation, which is usually a tablet. The term alkyl as used here means a branched or unbranched saturated unsubstituted carbon chain. In view of the required viscosities, the alkyl groups referred to in this paragraph do not comprise more than 6 carbon atoms.

- 35 The term pharmaceutically acceptable for suitable additives for use in carrying out the invention refers to requirements set for pharmaceutical auxiliaries in general. These requirements with regard to safety and non-interference with the active principle in pharmaceutical formulations are

- generally known to the skilled person. A standard compilation of pharmaceutically acceptable carriers and excipients can be found in the Handbook of Pharmaceutical excipients (2nd edition edited by A. Wade and P.J. Weller; Published by the American Pharmaceutical Association, Washington and The Pharmaceutical Press, London in 1994). Additives to a pharmaceutical formulation, such as carriers, binders, glidants, lubricants and colorants are used for example in order to obtain certain cohesiveness, coloration and flowability of the tablets. In a preferred embodiment of this invention magnesium stearate, colloidal silicon dioxide and iron oxide pigments are used.
- Glidants and lubricants are agents reducing the adhesiveness of the powder mixture or tablets during production. Methods of use of such additives are known in the art of making pharmaceutical compositions as for example described in chapter 19 of Remington's Pharmaceutical Sciences (18th edition Editor A.R. Gennaro; Mack Publishing Comp; Easton, Pennsylvania).
- Binders are agents used to impart cohesive properties to a pharmaceutical composition resulting in minimal loss from the pharmaceutical composition during production and handling. Carbohydrate binders are for example cellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, sugars, starches, amylopectin, dextrin, maltodextrin, gums and alginates. Microcrystalline cellulose, and in particular Avicel pH 101, is a preferred binder for use in this invention.
- The term pharmaceutical formulation for oral administration with extended release properties is used in this description to refer to the characteristics of extended release of gepirone according to the disclosure in EP 700 680. Specifically, a formulation according to the invention has a release rate of gepirone from the formulation such that about 18 to 24 hours are required to attain from about 90 to about 95% absorption of gepirone.

- Oral pharmaceutical formulations according to the present invention can be prepared by methods known in the art, e.g. as described in the standard reference, Gennaro et al., Remington's Pharmaceutical Sciences, (18th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical Preparations and Their Manufacture). Some caution in

handling the compressed high strength formulations of this invention is advisable in order to avoid breaking and cracks in tablets.

Gepirone may be prepared by any method known in the art. Typically the compound is prepared by the methods described in US patent No. 4,423,049. Pharmaceutical extended release compositions containing gepirone are disclosed in EP 700 680. The contents of these documents are incorporated herein by reference.

10 The following examples will serve to illustrate how to perform the invention.

Example 1:

15 Manufacturing procedure of batches of 160,000 tablets

Composition of tablets (Numbers in the table are amounts in mg)

Ingredients	40 mg	60 mg	80 mg	Function
Gepirone HCl	40.0	60.0	80.0	Active principle
Hydroxypropyl Methylcellulose (Methocel K100M, Premium)	290.0	290.0	290.0	Drug release controlling polymer
Microcrystalline Cellulose (Avicel pH 101)	52.12	31.0	33.7	Diluent
Euroxide yellow or red (E7055, E7056 or E7016)	0.08	1.2	3.5	Colorant
Colloidal silicon dioxide (cab-o-sil M5)	1.6	1.6	1.6	Glidant
Magnesium stearate NF	1.2	1.2	1.2	Lubricant

Active pre-mixture:

20 Transfer the colloidal silicon dioxide, NF, colorant (40 mg: Euroxide Yellow E 7056; 60 mg: Euroxide Yellow E 7055; 80 mg: Euroxide yellow E 7055 and Euroxide Red E 7016), gepirone HCl powder and 20% of hydroxypropyl methylcellulose USP in 2 cu. Ft. planetary mixer (Hobart mixer). Mix ingredients for 15 minutes in a planetary mixer (Hobart
25 Mixer). Label as 'Active Pre-Mix'.

Blend for slugging

Mill the Active Pre-Mix in a Fitzmill using a perforated plate No. 0020 at high speed, impact forward to deagglomerate lumps, if any.

5

Transfer the Active Pre-Mix in a 10 cu. Ft. "V"-blender without an I-bar, while passing through #12 mesh screen and transfer the balance of 80% HPMC, microcrystalline cellulose, NF and 50% of magnesium stearate, NF in the V-blender without an I-bar. Blend ingredients in the V-blender

10 without an I bar for 24 minutes and label as "Blend for Slugging".

Slugging

Compress the blend into slugs using 7/8" round flat face bevelled edge (40) bevelled plain (60, 80) tooling using a rotary Kikusui-Hercules

15 compression machine.

In process controls:

Weight:	2250 mg
Hardness:	7 kp
Targeted thickness:	0.255"

Final Blend

Mill the slugs in an S.S. Fitzmill with screw feeder using a perforated plate
20 No. 0093 at medium speed, knives forward and screw feeder setting of 3.5 ± 0.5 . Transfer the milled mass into a 10 cu. Ft. S.S. V-blender without I-bar. Screen the balance of 50% magnesium stearate, NF through # 18 mesh and transfer also into the V-blender. Blend for 6 minutes.

25 Compress tablets with a rotary Kikusui-Libra compression machine using 0.338" X 0.405" Ovoid rectangular dies.

In process controls:

Strength, mg	40 & 60	80
Run Weight, mg	385 ± 27	410 ± 29
Hardness, kp	18 ± 4	20 ± 8
Thickness, inches	0.230 to 0.260	0.235 to 0.265

Store in tight containers untill further use or testing.

30

Drug release profile of tablets prepared as described in this example.
Additional 20 mg tablets were made according to the procedure described in EP 700 680 for comparison of the drug release profile of the 60 and 80 tablets according to this invention,:

Gepirone release pattern of tablets (Numbers in the table represent the percentage dissolution of the theoretical content of the tablets)

Released after: →	1 hr	5 hr	12 hr	20 hr	recovery
20 mg tablets	19	49	77	93	102
40 mg tablets	21	50	77	93	100
60 mg tablets	21	51	81	97	102
80 mg tablets	22	52	80	96	101

Example 2

5

For upscaling the manufacturing for batches of 800,000 tablets certain adaptations were applied:

Thus, procedures are according to the methods described in example 1,
10 but the active pre-mix is blended in a 340 qt. AZMF Glen mixer for 28 minutes, the size of the V-blender used is 30 cu. Ft. and final blending is done for 7 minutes. Tablets had similar properties as measured in example 1. Special attention is given to the problem of friability of the 80 mg strength tablets. It is preferred to compress 80 mg tablets at a speed of
15 the compression machine of 20 rotations per minute, i.e. in general at a speed of less than 30 rpm, set at the tablet compression machine in order to reduce the number of tablets with cracks.

Claims

1. A pharmaceutical formulation for oral administration with extended
release properties comprising an amount of gepirone hydrochloride, an
5 amount of a cellulosic polymer matrix and an amount of
microcrystalline cellulose characterised in that the amount the
pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85
wt %, the amount of carbohydrate binder is from 7 to 10 wt % and the
amount of gepirone hydrochloride is from 13 to 21 wt %.
- 10 2. The pharmaceutical formulation according to claim 1, characterised in
that the cellulosic polymer matrix is a hydroxymethyl propylcellulose
having a viscosity of 15,000 cps to 100,000 cps.
- 15 3. The pharmaceutical formulation according to claim 1, characterised in
that the microcrystalline cellulose is Avicel pH 101.
4. A treatment for depression or a related central nervous system disorder
with gepirone administered in a once-a-day oral formulation for
20 extended release of gepirone, characterised in that the formulation is
according to claim 1.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 June 2002 (13.06.2002)

PCT

(10) International Publication Number
WO 02/045753 A3

(51) International Patent Classification⁷: **A61K 31/506**,
9/22

(21) International Application Number: PCT/EP01/14189

(22) International Filing Date:
30 November 2001 (30.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00204388.3 8 December 2000 (08.12.2000) EP

(71) Applicant: **AKZO NOBEL N.V.** [NL/NL]; Velperweg 76,
NL-6824 BM Arnhem (NL).

(72) Inventors: **EGBERINK, Johannes, Gerardus, Joseph**;
N.V. Organon, Postbus 20, NL-5340 BH Oss (NL). **EN-**
GELHART, John, Francis; Organon Inc., 375 Mt. Pleas-
ant Ave, West Orange, NJ 07092 (US).

(74) Agent: **KRAAK, Hajo**; P.O. Box 20, NL-5340 BH Oss
(NL).

(81) Designated States (*national*): AE, AG, AL, AU, BA, BB,
BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE,
GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR,
LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL,
RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:
— with international search report

(88) Date of publication of the international search report:
29 August 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: ORAL EXTENDED RELEASE FORMULATION OF GEPIRONE

(57) Abstract: This invention makes a pharmaceutical formulation for oral administration with extended release properties available comprising an amount of gepirone hydrochloride, an amount of a cellulosic polymer matrix and an amount of microcrystalline cellulose characterised in that the amount of the pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85 wt%, the amount of carbohydrate binder is from 7 to 10 wt% and the amount of gepirone hydrochloride is from 13 to 21 wt%. The formulation is useful for a treatment for depression or a related central nervous system disorder with gepirone administered in a once-a-day oral formulation for extended release of gepirone.

WO 02/045753 A3

INTERNATIONAL SEARCH REPORT

National Application No

/EP 01/14189

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/506 A61K9/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, CHEM ABS Data, SCISEARCH, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 700 680 A (SQUIBB BRISTOL MYERS CO) 13 March 1996 (1996-03-13) cited in the application the whole document claims	1-3
A	FEIGER A.D.: "A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression." PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/4 (659-665). XP001069219 the whole document page 660, column 1, paragraph 2	1-3



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

7 May 2002

Date of mailing of the international search report

04/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Luangkhot, N

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 01/17189

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WILCOX C.S.: "A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients"</p> <p>PSYCHOPHARMACOLOGY BULLETIN, (1996) 32/3 (335-342).</p> <p>XP001069224</p> <p>the whole document</p> <p>page 336, column 2</p>	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

P/EP 01/14189

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0700680	A	13-03-1996	US 5478572 A	26-12-1995
			AT 186462 T	15-11-1999
			AU 702282 B2	18-02-1999
			AU 3043895 A	21-03-1996
			CN 1128142 A	07-08-1996
			CZ 9502275 A3	13-03-1996
			DE 69513254 D1	16-12-1999
			DE 69513254 T2	15-06-2000
			DK 700680 T3	01-05-2000
			EP 0700680 A1	13-03-1996
			ES 2142432 T3	16-04-2000
			FI 954154 A	07-03-1996
			GR 3032598 T3	31-05-2000
			HK 1014666 A1	21-07-2000
			HU 73182 A2	28-06-1996
			IL 114984 A	28-10-1999
			JP 8183736 A	16-07-1996
			NO 953212 A	07-03-1996
			NZ 272855 A	26-05-1997
			PL 310298 A1	18-03-1996
			RU 2155044 C2	27-08-2000
			SG 30436 A1	01-06-1996
			ZA 9507144 A	26-03-1996

Form PCT/ISA/210 (patent family annex) (July 1992)